Current and emerging therapies for patients with advanced non-small-cell lung cancer

American Journal of Health-System Pharmacy

Volumn 67, Issue SUPPL. 1, 2010, Pages

  Sheth, Sheetal ^a  

^a US Oncology   (United States)

Author keywords

Antineoplastic agents; Bevacizumab; Cetuximab; Cisplatin; Combined therapy; Docetaxel; Erlotinib; Gemcitabine; Genetics; Lung neoplasms; Pemetrexed; Site of action; Toxicity; Vandetanib

Indexed keywords

BEVACIZUMAB; BEXAROTENE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYANOCOBALAMIN; DEXAMETHASONE; DOCETAXEL; ERLOTINIB; FOLIC ACID; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; PRINOMASTAT; VANDETANIB;

ACNE; ADVANCED CANCER; ANEMIA; ARTERY THROMBOSIS; BLEEDING; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CONFERENCE PAPER; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; HUMAN; HYPERTENSION; HYPONATREMIA; LUNG ADENOCARCINOMA; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 73949105112     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp090457     Document Type: Conference Paper

References (20)

1. Schneider PM, Metzger R, Brabender J et al. Lung cancer. In: Diamandis EP, Fritsche HA, Lilja H et al., eds. Tumor markers: physiology, pathobiology, technology, and clinical applications. Washington, DC: AACC Press; 2002.
2. National Comprehensive Cancer Network. National Comprehensive Cancer Network Guidelines V.2009. www.nccn.org/professionals/physician-gls/PDF/nscl.pdf (accessed 2009 Jun 30).
3. Smylie M, Mercier R, Aboulafia D et al. Phase III study of the matrix metallo-protease (MMP) inhibitor prinomastat in patients having advanced non-small cell lung cancer. Proc Am Soc Clin Oncol. 2001; 20:307a. Abstract.
4. Advani R, Lum BL, Fisher GA et al. A phase I trial of aprinocarsen (ISIS 3521/ LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer. Invest New Drugs. 2005; 23:467-77.
5. Herbst RS, Prager D, Hermann R et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005; 23:5892-9.
6. Blumenschein GR Jr, Khuri FR, von Pawel J et al. Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II. J Clin Oncol. 2008; 26:1879-85.
7. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355:2542-50.
8. Pirker R, Pereira JR, Szczesna A et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009; 373:1525-31.
9. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543-51.
10. Alimta (pemetrexed) prescribing information. Indianapolis, IN: Eli Lilly and Company; 2009.
11. Ciuleanu TE, Brodowicz T, Belani CP et al. Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: a phase III study. Paper presented at 44th American Society of Clinical Oncology Annual Meeting. Chicago, IL; 2008 May.
12. Belani CP, Brodowicz T, Ciuleanu T et al. Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: a randomized phase III study in advanced non-small cell lung cancer (NSCLC). Paper presented at 45th American Society of Clinical Oncology Annual Meeting. Orlando, FL; 2009 May.
13. Cappuzzo F, Ciuleanu T, Stelmakh L et al. SATURN: a double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. Paper presented at 45th American Society of Clinical Oncology Annual Meeting. Orlando, FL; 2009 May.
14. Thomson Reuters. OSI Pharmaceuticals submits supplemental new drug application to the FDA for Tarceva as a first-line maintenance therapy in advanced non-small cell lung cancer, www.reuters.com/article/pressRelease/ idUS52170+19-Mar-2009+BW20090319 (accessed 2009 Jul 21).
15. Miller VA, O'Connor P, Soh C et al. A randomized, double-blind, placebocontrolled, phase IIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). Paper presented at 45th American Society of Clinical Oncology Annual Meeting. Orlando, FL; 2009 May.
16. Lynch TJ, Bonomi PD, Butts C et al. Novel agents in the treatment of lung cancer: Fourth Cambridge Conference. Clin Cancer Res. 2007; 13:s4583-s4588.
17. Herbst RS, Sun Y, Korfee S et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZODIAC). Paper presented at 45th American Society of Clinical Oncology Annual Meeting. Orlando, FL; 2009 May.
18. De Boer R, Arrieta O, Gottfried M et al. Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZEAL). Paper presented at 45th American Society of Clinical Oncology Annual Meeting. Orlando, FL; 2009 May.
19. Natale RB, Thongprasert S, Greco FA et al. Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: a randomized, double-blind phase III trial (ZEST). Paper presented at 45th American Society of Clinical Oncology Annual Meeting. Orlando, FL; 2009 May.
20. Hainsworth J, Herbst R. A phase III, multicenter, placebo-controlled, double-blind, randomized clinical trial to evaluate the efficacy of bevacizumab (Avastin) in combination with erlotinib (Tarceva) compared with erlotinib alone for treatment of advanced non-small cell lung cancer after failure of standard first-line chemotherapy (BETA). Paper presented at 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology. Chicago, IL; 2008 Nov.